potential as a therapeutic platform and could help accelerate the development of therapeutic strategies for nervous system disorders.
In order to develop a programmable "machine-to-brain" communication platform, numerous criteria must be met, e.g., dosage precision, and dynamic spatial and temporal control.
Furthermore, delivery should preferably be achieved with minimal fluid flow, as liquid flow can lead to undesirable effects, e.g., chemical gradient disruption 9 , or increased pressure in compartments with limited volume. Non-convective delivery would enable introduction of biosubstances per se into small compartments in organs, e.g., the cochlea. Organic conjugated polymers have been investigated in recent years as delivery platforms that fulfil many of these requirements, in part due to their chemical and material properties which facilitate their incorporation into bio-medical devices 10, 11 . As volume-change actuators, they have been explored as reversible valves exposing drug-loaded microreservoirs 12 . This electrochemical actuation has also been investigated for the release of drugs from the polymer itself 13, 14 . Abidian et al. have even demonstrated controlled release from conducting polymer-coated drug-loaded nanofibers fabricated directly on a neural implant electrode 15 .
Each of these technologies takes advantage of the role of ions in polymer conduction.
Electronic and ionic conduction coexist -and are often coupled -in conducting polymer systems 16, 17 . Indeed, the fact that electronic conduction can be ion mediated leads to the conclusion that these materials could provide an ideal interface for signal transduction between electron-and ion-mediated systems. This concept was recently demonstrated in an organic electronic "ion pump" 18 . 23 .
To analyze whether we could expand the repertoire of signal substances transported through the electronic matrix, we tested the neurotransmitters glutamate (Glu), aspartate (Asp), and γ-amino butyric acid (GABA). These small molecules exist as positively charged ions depending on the pH, which is required for the electrophoretic action of the ion pump. Glu is the major excitatory neurotransmitter in the central nervous system (CNS) where it mediates fast synaptic transmission. Together with its receptors, Glu plays critical roles in synaptic plasticity, basic processes of memory and learning, brain development, as well as neurological and psychiatric disorders 24 . Asp is also an excitatory neurotransmitter, whereas GABA is the major inhibitory neurotransmitter in the mammalian CNS. The pathophysiology of numerous neuropsychiatric disorders, including anxiety and depression, are suggested to be due to disturbances in the GABA system 25 .
We prepared planar ion pump devices, comprising a single, biocompatible PEDOT:PSS layer, as previously reported 18 . The single film is divided by an electronically insulating -but still ionically conducting -region ( Figure 1 
The cations are electrophoretically transported through the region of film joining the two electrodes, then enter the cathodic side of the film, where they are delivered into the electrolyte. Using Glu, Asp, and GABA as source electrolytes, the delivery capabilities of the device were demonstrated at multiple driving voltages for a variety of times, with individual devices used for each parameter tested (Figures 2a-c) . By comparing the integrated electronic current to the quantity of neurotransmitters delivered into the target electrolyte (Supplementary Information), a transport efficiency can be defined by the electron:molecule ratio. This ratio is precisely 2.7 ± 0.2 for Glu (n = 16), 6.3 ± 0.5 for Asp (n = 10), and 1.3 ± 0.1 for GABA (n = 10) (value ± s.d.). For materials with low pK a , i.e., Glu and Asp, the excess protons present in the source solution will also be pumped. Owing to the smaller size of protons compared to Glu or Asp, their mobility through the channel can be significantly higher, explaining the larger electron:molecule ratios for Glu and Asp. The transport rate can be tuned by the operating voltage, providing a full range of transport up to quantities on the order of 100 µM in the total liquid volume. Locally however, the concentration can be significantly higher before the molecules diffuse away 23 . The approximate concentration of Glu in the synaptic cleft has been reported to be 2-1000 µM 26 , thus the device operates in a relevant physiological range.
The lifetime of the device is limited by the amount of oxidizable PEDOT (cf. Eqn. 1) and can thus be tailored by the electrode dimensions (Supplementary Information). The present electrode geometry allows for device operation on the order of 1 h in constant pumping mode,
i.e., constant current. The PEDOT could also be returned to a more reduced state, e.g., by reversing the voltage. Utilising pulsed delivery 23 , the lifetime should be bounded only by the concentration of molecules in the source electrolyte and could therefore be dramatically extended. Figure 2d illustrates that the delivery rate is stable after an initial equilibration period corresponding to the time required to fill the channel with the intended ions on first usage. The successful transport of neurotransmitters encouraged us to redesign the device into an encapsulated, syringe-like form to enable its use in vivo. The first step in this development was the realization that the channel region could comprise an additional electrolyte (Figure 1b) . This geometry could enable the central electrolyte to become the effective target system, with the original target acting simply as the electrochemical cathode. By "folding" this system, and providing encapsulation around the individual electrolytes, a syringe-like device is achieved (Figures 1c,d ). The operating principle is similar to the planar device, except that cations from the source are delivered to an external target electrolyte, and cations are extracted from this target region and drawn in toward the cathode system, completing the electrochemical circuit.
To ascertain whether the encapsulated device can be used for cell stimulation similarly to the planar device 18 , in vitro experiments were performed. Astrocytes, a sub-type of glial cells present in the CNS, express the receptor for Glu. Upon binding of Glu, membrane-bound ion channels open immediately, promoting Ca 2+ influx [27] [28] [29] . Therefore, astrocytes represent an ideal system to monitor Glu activation of cells using real-time single-cell ratiometric Ca 2+ imaging.
The device was loaded with Glu (source) and NaCl (cathodic) electrolytes and mounted with the tip in contact with the bottom of a dish, adjacent to primary murine astrocytes. After initial baseline recordings of intracellular Ca 2+ with the delivery device in the off-state, Glu transport was activated. A significant increase in intracellular Ca 2+ revealed successful delivery of Glu ( Figure   3 ) after an equilibration delay similar to that observed in Figure 2d . The Ca 2+ response declined when the voltage was turned off and cells re-established their basal intracellular Ca 2+ level. As a control, Glu was next applied manually using a pipette, resulting in a Ca 2+ response of similar magnitude to that induced by Glu delivered from the encapsulated device. Collectively, this substantiates the usability of the device for cell activation, and that Glu retains its potent biological form after transport through the polymer. Having demonstrated how this device converts electronic addressing signals into precise non-convective delivery of Glu, we next investigated its potential use as a novel communication interface between human-made electronics, selective neurotransmission, and brain function. To test the feasibility of this concept, we used the auditory system of the guinea pig as an in vivo experimental platform. Within the cochlea, sound waves of various frequencies are transduced primarily by the inner hair cell system, as opposed to the outer hair cell system 30 . As Glu is the primary neurotransmitter for the inner hair cells, the auditory system can be used to evaluate the ability of the device to target specific cells, i.e., whether the encapsulated ion pump can be used to selectively affect specific cell types in vivo. Excessive Glu is known to exert an excitotoxic effect on the inner hair cells as opposed to the outer hair cells 31, 32 , and this pathophysiological effect can be monitored by histological analysis. In addition, excitotoxicity can be analysed in real-time, by monitoring the auditory brainstem response (ABR). Excessive Glu will damage the inner hair cells, leading to hearing loss and an attenuated ABR. In the cochlea, high frequency sound waves are transduced at the base, near the round window membrane (RWM), while lower frequencies are transduced towards the apex. Therefore, shifts in ABR threshold (re:pretreatment threshold) at different frequencies indicate, in real-time, the effect of Glu at different distances up the cochlea. Currently, osmotic pumps are utilized to modulate such effects by direct fluid injection 33 . However, the inner hair cells, positioned on a delicate membrane that vibrates with sound stimulation, are highly mechanosensitive, e.g., to disturbances in fluid flow and pressure 34 . To bypass this problem, the ion pump can be used to deliver substances through the RWM, which is an established port of diffusive entry into the cochlea.
The tip of the delivery device was introduced in close proximity to the RWM of anesthetized guinea pigs using conventional ontological surgery (Figure 4a ). The procedure is non-invasive to the cochlea, since the device delivers Glu to the outside of the RWM through which Glu enters via diffusion (Figure 4b ). Once the device was in place, Glu was delivered continuously for 60 min (n = 5) and during this time, ABR shifts were assessed at 0, 15, 30 and 60 min. Within this timeframe, stimulation in the lower basal region (corresponding to 20 kHz transduction), upper basal region (16 kHz), and lower apical region (8 kHz) could be achieved without risking saturation of the entire cochlea with Glu. As the Glu solution was at low pH, control experiments (n = 3) delivering only H + were also performed. At 15 min, an ABR shift of only ~7.5 dB was observed for both Glu and H + for all frequencies, indicating the Glu concentration had yet to reach excitotoxic levels (Figure 4c ). At the 30 min time point, increased ABR shifts (~10 dB, data not shown) were observed in some cases for Glu while the H + response remained consistently low. After 60 min of Glu delivery, however, a strong, statistically significant ABR threshold shift (i.e., hearing loss) was noted at all frequencies, whereas the H + response remained consistently low. using cresyl violet (Figure 4d ). Control experiments revealed that delivered H + had little or no effect on any cell type. Similarly, no morphological changes were observed in the most apical regions of the cochlea after Glu was introduced into the perilymph (Supplementary Figure 1) .
However, in the lower and upper basal region, a strikingly large number of the dendrites of the inner, but not the outer hair cells, were observed to be swollen. Since these dendrites represent the major connection between the inner hair cells and the underlying auditory nerves, the damaging, excitotoxic effect of Glu explains the corresponding ABR shifts at these frequencies.
Collectively, these data indicate that the encapsulated ion pump can be used to establish concentration gradients within the perilymph, providing a means to spatially control excitotoxicity. Furthermore, this demonstrates that delivery of a particular neurotransmitter from the device can be used to selectively target a specific cell type in vivo, as responses are induced solely in the subset of cells expressing the relevant receptor.
Electronic control provides another highly desirable feature: the ability to expose cells to pulsed, rather than continuous delivery. Sustained exposure to neurotransmitters quickly desensitizes the receptors, reflected in, e.g., malfunctioning signalling pathways, or downregulation of receptor expression. Using pulsed delivery, such problems can be circumvented. In the present experiment, ~14 nmol of Glu was delivered during the 60 min "pulse". The device could accordingly be pulsed more than 100 times without depleting the ~30 µl Glu solution.
Tailoring the pulsing scheme according to the physiological requirements could increase the effective lifetime even further.
Having demonstrated the ability to translate electronic addressing signals, via neurotransmitter signalling, into brainstem responses, this technology establishes a new paradigm in machine-to-brain interfacing. Indeed, the device described herein is the first successful realization of an organic electronic device capable of modulating mammalian sensory function by precise delivery of neurotransmitters. These developments represent a significant step forward in biology-technology interfacing, and promise to pioneer further symbiosis of electronics and living systems.
Methods
Planar ion pump devices were fabricated using standard photolithographic methods as previously Encapsulated ion pump devices were fabricated in a similar fashion as the planar devices.
Devices were cut from the substrate using a computer-controlled plotter-table cutter, and sheathed with two pieces of silicone tubing each. The delivery-end of each tube was sealed and much of the length of the delivery "tip" was covered with the ion-impermeable silicone encapsulant Sylgard 186 (Dow Corning).
For in vitro testing, primary murine astrocyte cultures were prepared and maintained as previously described 35 , then loaded with the Ca 2+ -sensitive dye FURA-2 AM. The encapsulated device was evaluated by delivering Glu and observing the subsequent fluxes in intracellular [Ca 2+ ] via ratiometric time-lapse fluorescence microscopy. As a control, Glu was also applied manually using a pipette to a final concentration of 1 mM.
For in vivo testing of the encapsulated device, access to the RWM of the anesthetized guinea pig was achieved by a retro-auricle approach. Once the device was placed on the RWM, delivery using either 0. 
